The identification of markers predictive of response to chemotherapy (e.g., thymidylate synthase (TS) is a potential predictor of outcome after PMX; excision repair cross-complementation group 1 (ERCC1) as related to response to platinum) has been deeply evaluated in mesothelioma, although their predictive value in individual patients has not been fully validated [40,41,42]. Here, ERCC1 is linked to mesothelioma.